Browse POU5F1

Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Note=Expressed in a diffuse and slightly punctuate pattern.
Domain PF00046 Homeobox domain
PF00157 Pou domain - N-terminal to homeobox domain
Function

Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Critical for early embryogenesis and for embryonic stem cell pluripotency.

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001708 cell fate specification
GO:0001711 endodermal cell fate commitment
GO:0001714 endodermal cell fate specification
GO:0001824 blastocyst development
GO:0006417 regulation of translation
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0008356 asymmetric cell division
GO:0009299 mRNA transcription
GO:0009786 regulation of asymmetric cell division
GO:0010608 posttranscriptional regulation of gene expression
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0017148 negative regulation of translation
GO:0019827 stem cell population maintenance
GO:0031047 gene silencing by RNA
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0035019 somatic stem cell population maintenance
GO:0035194 posttranscriptional gene silencing by RNA
GO:0035195 gene silencing by miRNA
GO:0035987 endodermal cell differentiation
GO:0040029 regulation of gene expression, epigenetic
GO:0042789 mRNA transcription from RNA polymerase II promoter
GO:0045165 cell fate commitment
GO:0045727 positive regulation of translation
GO:0051302 regulation of cell division
GO:0060147 regulation of posttranscriptional gene silencing
GO:0060149 negative regulation of posttranscriptional gene silencing
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0060964 regulation of gene silencing by miRNA
GO:0060965 negative regulation of gene silencing by miRNA
GO:0060966 regulation of gene silencing by RNA
GO:0060967 negative regulation of gene silencing by RNA
GO:0060968 regulation of gene silencing
GO:0060969 negative regulation of gene silencing
GO:0098727 maintenance of cell number
Molecular Function GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0031625 ubiquitin protein ligase binding
GO:0035198 miRNA binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-1266738: Developmental Biology
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between POU5F1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between POU5F1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29855617Cervical CarcinomaInhibit immunityControl of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. miR-18a overexpression in CC cells is triggered by OCT4 overexpression.
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of POU5F1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of POU5F1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1950.744
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7220.731
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4760.847
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3890.385
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5810.471
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0440.955
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3610.797
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8340.672
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3430.245
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of POU5F1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POU5F1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POU5F1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POU5F1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POU5F1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of POU5F1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between POU5F1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPOU5F1
NamePOU class 5 homeobox 1
Aliases Oct4; MGC22487; OTF3; POU domain class 5, transcription factor 1; OTF-3; OTF4; Oct-3; Oct-4; POU class 5 hom ......
Chromosomal Location6p21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting POU5F1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.